Equity Overview
Price & Market Data
Price: $1.02
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $61,784,868
Volume: 0
Performance Metrics
1 Week: -2.86%
1 Month: -17.74%
3 Months: -41.71%
6 Months: -64.34%
1 Year: -67.62%
YTD: -40.70%
Company Details
Employees: 61
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.